Does BOTULINUM TOXIN TYPE A Cause Mobility decreased? 417 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 417 reports of Mobility decreased have been filed in association with BOTULINUM TOXIN TYPE A (Jeuveau). This represents 11.1% of all adverse event reports for BOTULINUM TOXIN TYPE A.
417
Reports of Mobility decreased with BOTULINUM TOXIN TYPE A
11.1%
of all BOTULINUM TOXIN TYPE A reports
411
Deaths
375
Hospitalizations
How Dangerous Is Mobility decreased From BOTULINUM TOXIN TYPE A?
Of the 417 reports, 411 (98.6%) resulted in death, 375 (89.9%) required hospitalization, and 374 (89.7%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BOTULINUM TOXIN TYPE A. However, 417 reports have been filed with the FAERS database.
What Other Side Effects Does BOTULINUM TOXIN TYPE A Cause?
Off label use (1,785)
Drug ineffective (1,175)
Drug intolerance (1,004)
Product use in unapproved indication (950)
Headache (797)
Migraine (775)
Maternal exposure during pregnancy (716)
Pain (714)
Hypoaesthesia (703)
Nausea (665)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which BOTULINUM TOXIN TYPE A Alternatives Have Lower Mobility decreased Risk?
BOTULINUM TOXIN TYPE A vs BREMELANOTIDE
BOTULINUM TOXIN TYPE A vs BRENTUXIMAB
BOTULINUM TOXIN TYPE A vs BRENTUXIMAB VEDOTIN
BOTULINUM TOXIN TYPE A vs BREO ELLIPTA
BOTULINUM TOXIN TYPE A vs BREXANOLONE